论文部分内容阅读
目的探讨低分子肝素钙治疗急性脑梗死的疗效和安全性。方法共纳入急性脑梗死患者60例,随机分为2组:治疗组和对照组,30例/组。对照组采用常规治疗,观察组在常规治疗的基础上加用低分子肝素钙5000IU,皮下注射,1次/天,连用7d。观察两组患者治疗前后的神经功能缺损评分和临床疗效。结果治疗组总有效率为93.3%,对照组总有效率为60.0%,治疗组临床疗效显著优于对照组(P<0.01)。结论低分子肝素钙治疗急性脑梗死安全有效,值得临床推广。
Objective To investigate the efficacy and safety of low molecular weight heparin in the treatment of acute cerebral infarction. Methods A total of 60 patients with acute cerebral infarction were enrolled and randomly divided into two groups: treatment group and control group, 30 cases / group. The control group was treated with conventional therapy. The observation group was given low molecular weight heparin 5000IU on the basis of routine treatment, subcutaneously, once daily for 7 days. The neurological deficit score and clinical efficacy of the two groups before and after treatment were observed. Results The total effective rate was 93.3% in the treatment group and 60.0% in the control group. The clinical efficacy of the treatment group was significantly better than that of the control group (P <0.01). Conclusion Low molecular weight heparin calcium is safe and effective in the treatment of acute cerebral infarction and is worthy of clinical promotion.